Consistent with evidence that reduction of glucagon receptor, GCGR, in papillary thyroid carcinoma resulted in the inactivation of EMT and P38/ERK pathways (Jiang et al., 2020), GCGR was down-regulated in LSCC and may serve as a potential prognostic biomarker and therapeutic target for LSCC. Here, MAPK1 is linked to thyroid gland papillary carcinoma.